The partnership will help MMS expand its award-winning services to pharma and biotech companies and extend MMS’ leadership in data-focused clinical research services. CANTON, Michigan – June 28, 2022 – MMS Holdings Inc. (“MMS” or the “Company”), a leading data-focused...

On PTSD Awareness Day, MAPS PBC announces plans to develop the New Drug Application for MDMA-assisted therapy in collaboration with MMS Holdings The second Phase 3 trial of the Breakthrough-Designated Therapy for PTSD will be completed in late 2022, with a targeted...

CANTON, Mich. (3/10/2022) – MMS Holdings, a data-focused contract research organization (CRO), announced the addition of Robert Allen, MD, as Principal Medical Director of Global Drug Safety and Pharmacovigilance to its team. Bringing more than 20 years of...

CANTON, Mich. (2/2/2022) - MMS Holdings, a data-focused clinical research organization, was recognized in the 2022 Top Workplace USA awards, a national list of organizations with strong company cultures and high employee satisfaction rates.    MMS, a minority and...

CANTON, Mich. (12/15/2021) – MMS Holdings Inc., an award-winning, data-focused CRO, announced a restructuring of their consulting services with the launch of a Project Advisory Services Unit to meet the needs of many small to mid-sized organizations in immediate,...

CANTON, Mich. (12/8/2021) - MMS Holdings, a data-focused CRO, is pleased to announce its selection as Best Contract Research Organization – Specialist Providers in the 2021 Scrip Awards.   The Scrip Awards, held annually by London-based Informa Pharma...